Role of β1–3-Adrenoceptors in Blood Pressure Control at Rest and During Tyramine-Induced Norepinephrine Release in Spontaneously Hypertensive Rats

T Berg, BW Piercey, J Jensen - Hypertension, 2010 - Am Heart Assoc
T Berg, BW Piercey, J Jensen
Hypertension, 2010Am Heart Assoc
β-Adrenoceptors contribute to hypertension in spite of the fact that β-adrenoceptor agonists
lower blood pressure. We aimed to differentiate between these functions and to identify
differences between spontaneously hypertensive and normotensive rats. β-Adrenoceptor
antagonists with different subtype selectivity or the ability to cross the blood-brain barrier
were used to demonstrate β-adrenoceptor involvement in resting blood pressure and the
response to tyramine-induced peripheral norepinephrine release. The centrally acting …
β-Adrenoceptors contribute to hypertension in spite of the fact that β-adrenoceptor agonists lower blood pressure. We aimed to differentiate between these functions and to identify differences between spontaneously hypertensive and normotensive rats. β-Adrenoceptor antagonists with different subtype selectivity or the ability to cross the blood-brain barrier were used to demonstrate β-adrenoceptor involvement in resting blood pressure and the response to tyramine-induced peripheral norepinephrine release. The centrally acting propranolol (β1+2[+3]), CGP20712A (β1), ICI-118551 (β2), and SR59230A (β3), as well as peripherally restricted nadolol (β1+2) and atenolol (β1), were administered intravenously, separately, or in combinations. Blood pressure, cardiac output, heart rate, total peripheral vascular resistance, and plasma catecholamine concentrations were evaluated. β-Adrenoceptor antagonists had little effect on cardiovascular baselines in normotensive rats. In hypertensive rats, antagonist-induced hypotension paralleled reductions in resistance, except for atenolol, which reduced cardiac output. The resistance reduction involved primarily neuronal catecholamine, central β1-adrenoceptors, and peripheral β2-adrenoceptors. Tyramine induced a transient, prazosin-sensitive vascular resistance increase. Inhibition of nerve-activated, peripheral β1/3-adrenoceptors enhanced this α1-adrenoceptor–dependent vasoconstriction in normotensive but not hypertensive rats. In hypertensive rats, return to baseline was eliminated after inhibition of the central β1-adrenoceptor, epinephrine release (acute adrenalectomy), and peripheral β2/3-adrenoceptors. Adrenalectomy eliminated β-adrenoceptor–mediated vasodilation in hypertensive rats, and tyramine induced a prazosin-sensitive vasoconstriction, which was inhibited by combined blockade of central β1- and peripheral β2-adrenoceptors. In conclusion, nerve-activated β1- and β3-adrenoceptor–mediated vasodilation was not present in hypertensive rats, whereas epinephrine-activated β2- and β3-adrenoceptor–mediated vasodilation was upregulated. There was also a hypertensive, nerve-activated vasoconstrictory mechanism present in hypertensive rats, involving central β1- and peripheral β2-adrenoceptors combined.
Am Heart Assoc